AbbVie | ABBV - Sales Revenues


AbbVie reported $16.99B in Sales Revenues for its fiscal quarter ending in June of 2026.





Sales Change Date
AbbVie USD 16.99B 1.99B Jun/2026
Abbott USD 13.01B 423M Sep/2026
ALKERMES USD 496.01M 103.1M Jun/2026
Amgen USD 10.1B 1.48B Jun/2026
AstraZeneca USD 15.38B 90M Jun/2026
Biogen USD 2.74B 490M Jun/2026
BioMarin Pharmaceutical USD 990M 224M Jun/2026
Bristol-Myers Squibb USD 12.97B 1.48B Jun/2026
Coherus Biosciences USD 12.75M 1.18M Dec/2025
Eisai JPY 234.33B 28.9B Jun/2026
Eli Lilly USD 22.97B 3.17B Jun/2026
Gilead Sciences USD 7.8B 800M Jun/2026
GlaxoSmithKline GBP 8.41B 781M Jun/2026
J&J USD 25.4B 89M Sep/2026
Medtronic USD 9.8B 0 Jun/2026
Merck USD 16.6B 310M Jun/2026
Neurocrine Biosciences USD 959M 148M Jun/2026
Novartis USD 14.52B 112M Sep/2026
Pacira USD 192.4M 15.4M Jun/2026
Perrigo USD 1.02B 51M Jun/2026
Pfizer USD 15.03B 530M Jun/2026
Regeneron Pharmaceuticals USD 4.29B 690M Jun/2026
Roche Holding CHF 30.36B 14.71B Jun/2026
Sanofi EUR 11.95B 710M Jun/2026
UCB EUR 4.25B 764M Dec/2025
Ultragenyx Pharmaceutical USD 214M 78M Jun/2026
United Therapeutics USD 783.3M 1.8M Jun/2026
Vertex Pharmaceuticals USD 3.33B 340M Jun/2026
Zoetis USD 2.5B 200M Jun/2026